ClinConnect ClinConnect Logo
Search / Trial NCT03749044

ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies

Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Nov 19, 2018

Trial Information

Current as of May 28, 2025

Completed

Keywords

Adverse Pregnancy Outcomes Sle Aspirin Adherence

ClinConnect Summary

The goal is to help improve counselling and ASA adherence for preeclampsia prevention in pregnant women with SLE. This study could offer the ideal setting for the conduct of a future study assessing the efficacy of ASA for prevention of placenta-mediated complications in SLE pregnancies.

For this trial, the investigator will recruit pregnant women with a SLE diagnosis based on the SLICC classification criteria, followed at the 6 Canadian SLICC centres (located in Toronto, Montreal, Halifax, Quebec, Winnipeg, and Calgary), at TRIO Fertility in Toronto and at Mary Pack Arthritis Centre, in V...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria
  • 1. Pregnant women with a SLE diagnosis based on the SLICC classification criteria;
  • 2. English and/or French speaking;
  • 3. Followed at participating sites;
  • 4. Gestational age up to 16-6/7 weeks\* inclusively
  • 5. Between the ages of 18 and 45 years;
  • 6. Only one pregnancy per woman will be included in the project;
  • 7. Single or multiple intrauterine pregnancies are permitted;
  • 8. Must be participating in the LEGACY Biobank. \*Our aim is to recruit subjects under or equal to 12 weeks but we will include pregnancies up to 16-6/7 weeks inclusively
  • Exclusion Criteria
  • 1. Pregnant women who do not meet the SLE diagnosis based on the SLICC classification;
  • 2. Women who do not speak English or French;
  • 3. Women who are not followed at participating sites;
  • 4. Gestational age at 17 weeks and above
  • 5. Under the age of 18 and over the age of 45;
  • 6. More than one pregnancy per woman will not be included in the project;
  • 7. Women with extrauterine pregnancies;
  • 8. Women who are not participating in the LEGACY Biobank;
  • 9. Women who cannot provide informed consent due to severe illness;
  • 10. Women who are cognitively impaired or incapable of understanding the text written on the consent form;
  • 11. Men are not eligible for this study.

About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre

The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.

Locations

Montréal, Quebec, Canada

Patients applied

0 patients applied

Trial Officials

Evelyne Vinet, MD/PhD

Principal Investigator

Research Institute of the McGill University Health Centre

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials